[1]
|
Bonnal, S.C., López-Oreja, I. and Valcárcel, J. (2020) Roles and Mechanisms of Alternative Splicing in Can-cer—Implications for Care. Nature Reviews Clinical Oncology, 17, 457-474.
https://doi.org/10.1038/s41571-020-0350-x
|
[2]
|
Zhang, S., Wu, X., Diao, P., et al. (2020) Identification of a Prognostic Alternative Splicing Signature in Oral Squamous Cell Carcinoma. Journal of Cellular Physiology, 235, 4804-4813. https://doi.org/10.1002/jcp.29357
|
[3]
|
Bernard, A., Boidot, R. and Végran, F. (2022) Alternative Splicing in Cancer and Immune Cells. Cancers, 14, Article No. 1726. https://doi.org/10.3390/cancers14071726
|
[4]
|
Chabot, B. and Shkreta, L. (2016) Defective Control of Pre-Messenger RNA Splicing in Human Disease. Journal of Cell Biology, 212, 13-27.
|
[5]
|
David, C.J. and Manley, J.L. (2010) Alternative Pre-MRNA Splicing Regulation in Cancer: Pathways and Programs Unhinged. Genes & Development, 24, 2343-2364. https://doi.org/10.1101/gad.1973010
|
[6]
|
Ding, Y., Feng, G. and Yang, M. (2020) Prognostic Role of Alternative Splicing Events in Head and Neck Squamous Cell Carcinoma. Cancer Cell International, 20, Article No. 168. https://doi.org/10.1186/s12935-020-01249-0
|
[7]
|
Donoghue, M.T.A., Schram, A.M., Hyman, D.M., et al. (2020) Discovery through Clinical Sequencing in Oncology. Nature Cancer, 1, 774-783. https://doi.org/10.1038/s43018-020-0100-0
|
[8]
|
Wright, C.J., Smith, C.W.J. and Jiggins, C.D. (2022) Alternative Splicing as a Source of Phenotypic Diversity. Nature Reviews Genetics, 23, 697-710. https://doi.org/10.1038/s41576-022-00514-4
|
[9]
|
Murphy, A.J., Li, A.H., Li, P. and Sun, H. (2022) Therapeutic Targeting of Alternative Splicing: A New Frontier in Cancer Treatment. Frontiers in Oncology, 12, Article ID: 868664. https://doi.org/10.3389/fonc.2022.868664
|
[10]
|
Lee, Y. and Rio, D.C. (2015) Mechanisms and Regulation of Al-ternative Pre-MRNA Splicing. Annual Review of Biochemistry, 84, 291-323. https://doi.org/10.1146/annurev-biochem-060614-034316
|
[11]
|
Wang, S., Wang, S., Zhang, X., Meng, D., Xia, Q., Xie, S., Shen, S., Yu, B., Hu, J., Liu, H. and Yan, W. (2022) Comprehensive Analysis of Prognosis-Related Alternative Splicing Events in Ovarian Cancer. RNA Biology, 19, 1007-1018.
https://doi.org/10.1080/15476286.2022.2113148
|
[12]
|
Gansler, T., Ganz, P.A., Grant, M., et al. (2010) Sixty Years of CA: A Cancer Journal for Clinicians. CA: A Cancer Journal for Clinicians, 60, 345-350. https://doi.org/10.3322/caac.20088
|
[13]
|
Eisenhauer, E.A. (2017) Real-World Evidence in the Treatment of Ovarian Cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 28, viii61-viii65. https://doi.org/10.1093/annonc/mdx443
|
[14]
|
Siegel, R.L., Miller, K.D., Fuchs, H.E. and Jemal, A. (2021) Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71, 7-33. https://doi.org/10.3322/caac.21654
|
[15]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[16]
|
Yao, S., Yuan, C., Shi, Y., Qi, Y., Sridha, R., Dai, M. and Cai, H. (2022) Alternative Splicing: A New Therapeutic Target for Ovarian Cancer. Technology in Cancer Research & Treatment, 21.
https://doi.org/10.1177/15330338211067911
|
[17]
|
Hu, Z., Artibani, M., Alsaadi, A., et al. (2020) The Repertoire of Serous Ovarian Cancer Non-Genetic Heterogeneity Revealed by Single-Cell Sequencing of Normal Fallopian Tube Epi-thelial Cells. Cancer Cell, 37, 226-242.
https://doi.org/10.1016/j.ccell.2020.01.003
|
[18]
|
Lheureux, S., Gourley, C., Vergote, I. and Oza, A.M. (2019) Epi-thelial Ovarian Cancer. The Lancet, 393, 1240-1253.
https://doi.org/10.1016/S0140-6736(18)32552-2
|
[19]
|
Jeong, H.M., Han, J., Lee, S.H., Park, H.J., Lee, H.J., Choi, J.S., et al. (2017) ESRP1 Is Overexpressed in Ovarian Cancer and Promotes Switching from Mesenchymal to Epithelial Phenotype in Ovarian Cancer Cells. Oncogenesis, 6, E391. https://doi.org/10.1038/oncsis.2017.89
|
[20]
|
Pereira, B., Billaud, M. and Almeida, R. (2017) RNA-Binding Proteins in Cancer: Old Players and New Actors. Trends in Cancer, 3, 506-528. https://doi.org/10.1016/j.trecan.2017.05.003
|
[21]
|
Hong, S. (2017) RNA Binding Protein as an Emerging Therapeutic Target for Cancer Prevention and Treatment. Journal of Cancer Prevention, 22, 203-210. https://doi.org/10.15430/JCP.2017.22.4.203
|
[22]
|
Cretu, C., Schmitzova, J., Ponce-Salvatierra, A., Dybkov, O., De Laurentiis, E.I., Sharma, K., et al. (2016) Molecular Architecture of SF3b and Structural Consequences of Its Can-cer-Related Mutations. Molecular Cell, 64, 307-319.
https://doi.org/10.1016/j.molcel.2016.08.036
|
[23]
|
Diao, Y., Li, Y., Wang, Z., Wang, S., Li, P. and Kong, B. (2022) SF3B4 Promotes Ovarian Cancer Progression by Regulating Alternative Splicing of RAD52. Cell Death & Disease, 13, 179. https://doi.org/10.1038/s41419-022-04630-1
|
[24]
|
Haferlach, T., et al. (2014) Landscape of Genetic Lesions in 944 Patients with Myelodysplastic Syndromes. Leukemia, 28, 241-247.
|
[25]
|
Darman, R.B., et al. (2015) Can-cer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3’ Splice Site Selection through Use of a Different Branch Point. Cell Reports, 13, 1033-1045. https://doi.org/10.1016/j.celrep.2015.09.053
|
[26]
|
Qian, Y., Chen, Y. and Li, X. (2021) CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* Tetramutation Co-Contribute to Myeloblast Transformation in a Chronic Neutrophilic Leukemia. Annals of Hematology, 100, 1459-1461. https://doi.org/10.1007/s00277-021-04491-2
|
[27]
|
Obeng, E., Chappell, R., Seiler, M., et al. (2016) Physiologic Expression of Sf3b1K700E Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceo-some Modulation. Cancer Cell, 30, 404-417.
https://doi.org/10.1016/j.ccell.2016.08.006
|
[28]
|
Shirai, C.L., Ley, J.N., White, B.S., et al. (2015) Mutant U2AF1 Expression Alters Hematopoiesis and Pre-MRNA Splicing in Vivo. Cancer Cell, 27, 631-643. https://doi.org/10.1016/j.ccell.2015.04.008
|
[29]
|
Wang, Z., Wang, S., Qin, J., Zhang, X., Lu, G., Liu, H., Guo, H., Wu, L., Shender, V.O., Shao, C., Kong, B. and Liu, Z. (2022) Splicing Factor BUD31 Promotes Ovarian Cancer Pro-gression through Sustaining the Expression of Anti-Apoptotic BCL2L12. Nature Communications, 13, Article No. 6246. https://doi.org/10.1038/s41467-022-34042-w
|
[30]
|
Wang, C.K., Chen, T.J., Tan, G.Y.T., Chang, F.P., Sridharan, S., Yu, C.A., Chang, Y.H., Chen, Y.J., Cheng, L.T. and Hwang-Verslues, W.W. (2023) MEX3A Mediates P53 Degrada-tion to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis. Cancer Research, 83, 251-263. https://doi.org/10.1158/0008-5472.CAN-22-1159
|
[31]
|
Li, F., Zhao, C., Diao, Y., Wang, Z., Peng, J., Yang, N., Qiu, C., Kong, B. and Li, Y. (2022) MEX3A Promotes the Malignant Progression of Ovarian Cancer by Regulating In-tron Retention in TIMELESS. Cell Death & Disease, 13, Article No. 553. https://doi.org/10.1038/s41419-022-05000-7
|
[32]
|
Yoshida, K. and Miki, Y. (2010) Role of BRCA1 and BRCA2 as Regulators of DNA Repair, Transcription, and Cell Cycle in Response to DNA Damage. Cancer Science, 95, 866-871. https://doi.org/10.1111/j.1349-7006.2004.tb02195.x
|
[33]
|
Li, Y., Chen, Z., Peng, J., Yuan, C., Yan, S., Yang, N., Li, P. and Kong, B. (2023) The Splicing Factor SNRPB Promotes Ovarian Cancer Progression through Regulating Ab-errant Exon Skipping of POLA1 and BRCA2. Oncogene, 42, 2386-2401. https://doi.org/10.1038/s41388-023-02763-x
|
[34]
|
Wang, S., Wang, Z., Li, J., Qin, J., Song, J., Li, Y., et al. (2021) Splicing Factor USP39 Promotes Ovarian Cancer Malignancy through Maintaining Efficient Splicing of Oncogenic HMGA2. Cell Death & Disease, 12, Article No. 294.
https://doi.org/10.1038/s41419-021-03581-3
|
[35]
|
Hsu, K.F., Shen, M.R., Huang, Y.F., Cheng, Y.M., Lin, S.H., Chow, N.H., et al. (2015) Overexpression of the RNA- Binding Proteins Lin28B and IGF2BP3 (IMP3) Is Associated with Chemoresistance and Poor Disease Outcome in Ovarian Cancer. British Journal of Cancer, 113, 414-424. https://doi.org/10.1038/bjc.2015.254
|
[36]
|
Pellarin, I., Dall’Acqua, A., Gambelli, A., Pellizzari, I., D’Andrea, S., Sonego, M., et al. (2020) Splicing Factor Proline- and Glutamine-Rich (SFPQ) Protein Regulates Platinum Response in Ovarian Cancer-Modulating SRSF2 Activity. Oncogene, 39, 4390-4403. https://doi.org/10.1038/s41388-020-1292-6
|
[37]
|
Zhao, L., Wang, W., Huang, S., Yang, Z., Xu, L., Yang, Q., et al. (2018) The RNA Binding Protein SORBS2 Suppresses Metastatic Colonization of Ovarian Cancer by Stabilizing Tu-mor-Suppressive Immunomodulatory Transcripts. Genome Biology, 19, Article No. 35. https://doi.org/10.1186/s13059-018-1412-6
|
[38]
|
Zhang, D., Zou, D., Deng, Y. and Yang, L. (2021) Systematic Analysis of the Relationship between Ovarian Cancer Prognosis and Alternative Splicing. Journal of Ovarian Research, 14, Article No. 120.
https://doi.org/10.1186/s13048-021-00866-1
|
[39]
|
Yin, H., Wang, J., Li, H., Yu, Y., Wang, X., Lu, L., Lv, C., Chang, B., Jin, W., Guo, W., et al. (2021) Extracellular Matrix Protein-1 Secretory Isoform Promotes Ovarian Cancer through Increasing Alternative MRNA Splicing and Stemness. Nature Communications, 12, Article No. 4230. https://doi.org/10.1038/s41467-021-24315-1
|
[40]
|
Marima, R., Francies, F.Z., Hull, R., Molefi, T., Oyomno, M., Khanyile, R., Mbatha, S., Mabongo, M., Owen Bates, D. and Dlamini, Z. (2021) MicroRNA and Alternative MRNA Splicing Events in Cancer Drug Response/Resistance: Potent Therapeutic Targets. Biomedicines, 9, Article No. 1818. https://doi.org/10.3390/biomedicines9121818
|
[41]
|
陈延君, 刘晓菲, 刘涵, 等. 中医药干预肿瘤相关巨噬细胞极化治疗乳腺癌的研究进展[J]. 中国现代普通外科进展, 2023, 26(9): 741-744.
|